ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.

James Larkin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.